Implandata Ophthalmic Products GmbH (Implandata) is a medical technology company that has been located in Hanover, Germany, since it was founded.

Having received CE approval for the EYEMATE™ system in 2017, Implandata will soon bring the product onto the European market. The EYEMATE™ system enables patients to measure intra-ocular pressure themselves, and make adjustments in keeping with their everyday needs. A telemedicine connection to the system makes it possible for doctors to make adjustments to the therapy for individual patients in a timely manner. Consequently, it is possible to prevent vision loss in glaucoma patients, and at the same time, increase life expectancy and cut healthcare costs.

Initial investment:

B2G Partner:
Günter Steffen



Founding and seed financing
Monocentric first-in-human pilot study provides proof-of-concept and yields crucial design feedback for final product
Granting of key industrial property rights
Multicentric clinical trials in pursuit of CE approval
CE approval and preparation for market launch

“B2G helped us at a decisive stage in the development of our business, with financial support and expertise, so that we were able to reach key milestones on the path toward marketing our product.”

Max Ostermeier
Founder and CEO